Viral Vector and Plasmid DNA Manufacturing Market Overview:
Global Viral Vector And Plasmid DNA Manufacturing Market accounted for $261 million in 2016, and is expected to reach $1090 million by 2023, registering a CAGR of 22.6% from 2017 to 2023. Viral vectors and plasmid DNA manufacturing commonly includes the use of system biology and panomics to determine the cause of a patient's illness at the molecular level, followed by the use of concentrated medications to address each patient's illness. Moreover, viral vectors and plasmid DNA can reduce the cost of treatment and help decrease repeated administration of medications.
The global viral vectors and plasmid DNA manufacturing market is expected to grow at a productive rate during the forecast period, owing to surge in global incidence of cancer and increase in geriatric population susceptible to disease. Moreover, government initiatives & grants and increase in investment by private companies on R&D activities of viral vectors and plasmid DNA manufacturing are expected to boost the market growth. Furthermore, untapped potential of developing countries provides lucrative opportunities to the market players.
The global viral vectors and plasmid DNA manufacturing market is segmented based on product, application, and geography. Based on product, it is divided into plasmid DNA, viral vectors, and non-viral vectors. Based on application, it is categorized into cancer, inherited disorders, viral infections, and others. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Viral Vector and Plasmid DNA Manufacturing Market, By Geography, 2016-2023 ($Million)
North America generated the highest revenue in the viral vector and plasmid DNA manufacturing market in 2016. Asia-Pacific possesses high market potential, owing to increase in awareness about vector products, and rise in viral and non-viral vector applications. This region is anticipated to experience fast-paced growth, in terms of development and use of viral vector and plasmid DNA.
Viral Vector and Plasmid DNA Manufacturing Market, By Product, 2016-2023 ($Million)
Viral vectors occupied the largest share in the viral vector and plasmid DNA manufacturing market, owing to the sheer necessity and applicability of these products in different research interventions.
Viral Vector and Plasmid DNA Manufacturing Market, By Application, 2016-2023 ($Million)
The report provides extensive competitive analysis and profiles of key market players, such as Kaneka Eurogentec S.A., FinVector, Brammer Bio, Cell and Gene Therapy Catapult, FUJIFILM Diosynth Biotechnologies, Sanofi, Spark Therapeutics, Cobra Biologics, UniQure and MassBiologics. Other players in the value chain analysis include, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Ltd., and Thermo Fisher Scientific, Inc.
Key Market Benefits:
- The study provides an in-depth analysis of the global viral vector and plasmid DNA manufacturing market with the current trends and future estimations to elucidate the imminent investment pockets.
- It presents quantitative analysis of the market from 2017 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the market based on application assists in understanding the trends in the industry.
- Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the industry.
Viral Vector and Plasmid DNA Manufacturing Market Key Segments:
- Plasmid DNA
- Viral Vectors
- Non-viral Vectors
- Inherited Disorders
- Viral Infections
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA